DeepMed Research

The Sidney Kimmel Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Employees: -

Market Cap: -

Website: http://www.hopkinsmedicine.org/kimmel_cancer_center

Clinical Trials

Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma

Phase 2

Withdrawn

Conditions: Pancreatic Neoplasms

Interventions: Drug: Gemcitabine/Gemzar
Procedure: Laparoscopic Distal pancreatectomy

First Posted Date: 2010-01-11

Last Posted Date: 2016-10-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT01045941

Locations: 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Biological: Activated marrow infiltrating lymphocytes
Biological: Allogeneic Myeloma Vaccine
Drug: Cyclophosphamide
Biological: Filgrastim
Procedure: Leukapheresis
Drug: Melphalan
Biological: Autologous stem cell transplant

First Posted Date: 2010-01-11

Last Posted Date: 2021-04-09

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 36

Registration Number: NCT01045460

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN

Phase 1

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: RAD001
Drug: Cetuximab
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2009-11-06

Last Posted Date: 2018-07-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 9

Registration Number: NCT01009346

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Study of Blood Samples and Risk of Infection in Patients With Newly Diagnosed Malignant Supratentorial Astrocytoma

Completed

Conditions: Brain and Central Nervous System Tumors
Infection

First Posted Date: 2009-10-22

Last Posted Date: 2012-05-28

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 104

Registration Number: NCT00999622

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

Phase 1

Completed

Conditions: HPV16 Positive
Cervical Intraepithelial Neoplasia (CIN 2/3)

Interventions: Biological: DNA vaccination
Device: Gene gun vaccine
Biological: intramuscular vaccination
Biological: intra-lesional vaccine administration
Procedure: therapeutic resection of the lesion
Drug: imiquimod

First Posted Date: 2009-10-02

Last Posted Date: 2018-07-09

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 132

Registration Number: NCT00988559

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Johns Hopkins Outpatient Center, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

124I-FIAU Imaging in EBV and KSHV Associated Cancers

Not Applicable

Completed

Conditions: Gastric Cancer
Hodgkin Lymphoma
Non Hodgkin Lymphoma
Kaposi's Sarcoma
Nasopharyngeal Cancer

Interventions: Other: FIAU-PET-CT-4
Other: FIAU-PET-CT-2

First Posted Date: 2009-09-23

Last Posted Date: 2018-09-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 12

Registration Number: NCT00982449

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Study to Evaluate the Effect of Sulforaphane in Broccoli Sprout Extract on Breast Tissue

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Broccoli sprout extract
Drug: Mango juice

First Posted Date: 2009-09-23

Last Posted Date: 2018-11-21

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 34

Registration Number: NCT00982319

Locations: 🇺🇸
Johns Hopkins Medical Institution, Baltimore, Maryland, United States

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: allogeneic GM-CSF-secreting breast cancer vaccine
Biological: trastuzumab
Drug: cyclophosphamide

First Posted Date: 2009-09-04

Last Posted Date: 2019-04-24

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 63

Registration Number: NCT00971737

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Phase 1

Completed

Conditions: Sarcoma

Interventions: Drug: temsirolimus plus liposomal doxorubicin

First Posted Date: 2009-07-30

Last Posted Date: 2019-03-11

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 24

Registration Number: NCT00949325

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab

Phase 2

Terminated

Conditions: Lymphoma
B-cell Lymphoma
Non Hodgkin Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total body irradiation
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Rituximab
Biological: Allogeneic Bone Marrow Transplant (BMT)

First Posted Date: 2009-07-24

Last Posted Date: 2018-08-27

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 135

Registration Number: NCT00946023

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy